Novadiscovery develops JINKO, a best-in-class in silico clinical trial simulation platform that combines disease models, virtual patients and trial workflows to predict clinical benefit and optimize study design. JINKO provides an integrated suite of applications spanning Discovery to Market Access and its workflows are designed to closely resemble real-life clinical studies. The company leverages a decade of disease modeling and simulation expertise and employs a team of around 30 scientists, engineers and clinicians. Novadiscovery says its technology aims to improve R&D productivity and accelerate or de-risk clinical development decisions. The company plans to advance JINKO, expand into the U.S., and build a COVID-19 disease model in collaboration with Sanofi. Novadiscovery is headquartered in Lyon, France. Novadiscovery develops an in silico clinical trial simulation platform, Jinkō®, which combines mechanistic disease and treatment models with artificial intelligence and virtual patients to predict clinical benefit before human trials. The platform is indication‑agnostic and has been deployed in immuno‑oncology, orphan diseases, metabolic diseases and cardiotherapy. Novadiscovery plans to scale Jinkō® into a SaaS offering so clients can directly run their own in silico trials and to develop additional disease models. The company intends to use the financing to grow its presence in the US market, the largest market for drug development. Novadiscovery positions its technology as a way to reduce R&D costs, compress time‑to‑market and de‑risk R&D decisions, including in data‑poor environments. The company is headquartered in Lyon, France and assembles a team of about 30 scientists, engineers and clinicians.

Total raised

$9M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2021